Oncogenic Kras and Notch-1 cooperate in T-cell acute lymphoblastic leukemia/lymphoma

References

• Kindler T, Cornejo MG, Scholl C et al. K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch-1 mutations and are sensitive to γ-secretase inhibitors. Blood112(8), 3373–3382 (2008).
   PubMed Web of Science ®Google Scholar
• Weng AP, Millholland JM, Yashiro-Ohtani Y et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev.20(15), 2096–2109 (2006).
   PubMed Web of Science ®Google Scholar
• Mansour MR, Linch DC, L Foroni, Goldstone AH, Gale RE. High incidence of NOTCH1 mutations in adult patients with T-cell acute lymphoblastic leukemia. Leukemia20, 537–539 (2006).
   PubMed Web of Science ®Google Scholar
• Maser RS, Choudhury B, Campbell PJ et al. Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature447(7147), 966–971 (2007).
   PubMed Web of Science ®Google Scholar
• Flex E, Petrangeli V, Stella L, Chiaretti S et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. Exp. Med.205(4), 751–758 (2008).
   PubMed Web of Science ®Google Scholar
• Palomero T, Sulis ML, Cortina M et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat. Med.13(10), 1203–1210 (2007).
   PubMed Web of Science ®Google Scholar
• Ferrando AA, Neuberg DS, Staunton J et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell1(1), 75–87 (2002).
   PubMed Web of Science ®Google Scholar
• Chervinsky DS, Zhao XF, Lam DH, Ellsworth M, Gross KW, Aplan PD. Disordered T-cell development and T-cell malignancies in SCL LMO1 double-transgenic mice: parallels with E2A-deficient mice. Mol. Cell. Biol.19, 5025–5035 (1999).
   PubMedGoogle Scholar
• Yan W, Young AZ, Soares VC, Kelley R, Benezra R, Zhuang Y. High incidence of T-cell tumors in E2A-null mice and E2A/Id1 double-knockout mice. Mol. Cell. Biol.17, 7317–7327 (1997).
   PubMedGoogle Scholar
• O’Neil J, Calvo J, McKenna K et al. Activating Notch-1 mutations in mouse models of T-ALL. Blood107, 781–785 (2006).
   PubMed Web of Science ®Google Scholar
• Shank-Calvo JA, Draheim K, Bhasin M, Kelliher MA. p16Ink4a or p19Arf loss contributes to Tal1-induced leukemogenesis in mice. Oncogene25, 3023–3031 (2006).
   PubMedGoogle Scholar
• Bourne HR, Sanders DA, McCormick F. The GTPase superfamily: conserved structure and molecular mechanism. Nature349, 117–127 (1991).
   PubMed Web of Science ®Google Scholar
• Boguski MS, McCormick F. Proteins regulating Ras and its relatives. Nature366, 643–654 (1993).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Viciana P, Warne PH, Dhand R et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature370, 527–532 (1994).
   PubMed Web of Science ®Google Scholar
• Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. Cancer7, 295–308 (2007).
   PubMed Web of Science ®Google Scholar
• Perentesis JP, Bhatia S, Boyle E et al.RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia. Leukemia18, 685–692 (2004).
   PubMed Web of Science ®Google Scholar
• von Lintig FC, Huvar I, Law P, Diccianni MB, Yu AL, Boss GR. Ras activation in normal white blood cells and childhood acute lymphoblastic leukemia. Clin. Cancer Res.6, 1804–1810 (2000).
   PubMedGoogle Scholar
• Chan IT, Kutok JL, Williams IR et al. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J. Clin. Invest.113, 528–538 (2004).
   PubMed Web of Science ®Google Scholar
• Braun BS, Tuveson DA, Kong N et al. Somatic activation of oncogenic Krasin hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. Proc. Natl Acad. Sci. USA101, 597–602 (2004).
   PubMed Web of Science ®Google Scholar
• Nam CH, Rabbitts TH. The role of LMO2 in development and in T cell leukemia after chromosomal translocation or retroviral insertion. Mol. Ther.13(1), 15–25 (2006).
   PubMedGoogle Scholar
• Larson RC, Lavenir I, Larson TA et al. Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice. EMBO J.15(5), 1021–1027 (1996).
   PubMed Web of Science ®Google Scholar
• Kelliher MA, Seldin DC, Leder P. Tal-1 induces T cell acute lymphoblastic leukemia accelerated by casein kinase IIα. EMBO J.15, 5160–5166 (1996).
   PubMedGoogle Scholar
• Zhang J, Wang J, Liu Y et al. Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation. Blood113(6), 1304–1314 (2009).
   PubMed Web of Science ®Google Scholar
• Robey EA, Bluestone JA. Notch signaling in lymphocyte development and function. Curr. Opin. Immunol.16(3), 360–366 (2004).
   PubMed Web of Science ®Google Scholar
• Malecki MJ, Sanchez-Irizarry C, Mitchell JL et al. Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes. Mol. Cell. Biol.26, 4642–4651 (2006).
   PubMed Web of Science ®Google Scholar
• Eguchi-Ishimae M, Eguchi M, Kempski H, Greaves M. NOTCH1 mutation can be an early, prenatal genetic event in T-ALL. Blood111(1), 376–378 (2008).
   PubMedGoogle Scholar
• Pear WS, Aster JC, Scott ML et al. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J. Exp. Med.183, 2283–2291 (1996).
   PubMed Web of Science ®Google Scholar
• Chiang MY, Xu L, Shestova O et al. Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. J. Clin. Invest.118(9), 3181–3194 (2008).
   PubMed Web of Science ®Google Scholar
• Lin YW, Nichols RA, Letterio JJ, Aplan PD. Notch-1 mutations are important for leukemic transformation in murine models of precursor-T leukemia/lymphoma. Blood107, 2540–2543 (2006).
   PubMed Web of Science ®Google Scholar
• Mansour MR, Duke V, Foroni L, Patel B et al. NOTCH1 mutations are secondary events in some patients with T-cell acute lymphoblastic leukemia. Clin. Cancer Res.13(23), 6964–6969 (2007).
   PubMed Web of Science ®Google Scholar
• Howe SJ, Mansour MR, Schwarzwaelder K et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J. Clin. Invest.118(9), 3143–3150 (2008).
   PubMed Web of Science ®Google Scholar
• Gordon WR, Roy M, Vardar-Ulu D et al. Structure of the Notch1 negative regulatory region: implications for normal activation and pathogenic signaling in T-ALL. Blood (2008) (Epub ahead of print).
   Google Scholar
• Sulis ML, Williams O, Palomero T et al. NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. Blood112(3), 733–740 (2008).
   PubMed Web of Science ®Google Scholar
• Weijzen S, Rizzo P, Braid M et al. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat. Med.8, 979–986 (2002).
   PubMed Web of Science ®Google Scholar